This study evaluates the effect of CCX168, a C5aR Antagonist, Oral Administration on Ex Vivo
Thrombus Formation and Disease Activity in ten patients with diagnosis of Atypical Hemolytic
Uremic Syndrome with or without genetic abnormalities in the complement system or
thrombomodulin, on stable chronic extracorporeal or peritoneal dialysis therapy since at
least 6 months.
Phase:
Phase 2
Details
Lead Sponsor:
Mario Negri Institute for Pharmacological Research